Keywords: cephalon, turnover, rockets, 2nd, quarter, nasdaq-listed, announced
Cephalon turnover rockets in 2nd quarter
Article | 12 August 2002
Nasdaq-listed Cephalon has announced product sales of $108.8 million forsecond-quarter 2002, an increase of 145% on the like, year-earlier period. Earnings per share ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
